Refers to a method for treating a Human Patient affected with Multiple Sclerosis or presents a clinically isolated Syndrome comprising orally administering to the patient a dose of laquinimod and injected subcutaneously Daily, a daily dose of 20 mg of glatiramer acetate, pref The laquinimod technology is laquinimod sodium. It also relates to a Pharmaceutical compositionREFERIDA A UN METODO PARA TRATAR UN PACIENTE HUMANO AFECTADO CON ESCLEROSIS MULTIPLE O QUE PRESENTA UN SINDROME CLINICAMENTE AISLADO QUE COMPRENDE ADMINISTRAR ORALMENTE AL PACIENTE UNA DOSIS DIARIA DE LAQUINIMOD E INYECTAR SUBCUTANEAMENTE UNA DOSIS DIARIA DE 20 MG DE ACETATO DE GLATIRAMERO, DE PREFERENCIA EL LAQUINIMOD ES LAQUINIMOD SODICO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA
